This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
09 May 2014
In the version of this article initially published, Andrew Robertson was incorrectly identified with the last name Anderson. The error has been corrected in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jayaraman, K. Biocon's first-in-class anti-CD6 mAb reaches the market. Nat Biotechnol 31, 1062–1063 (2013). https://doi.org/10.1038/nbt1213-1062b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1213-1062b